Categories: All postsInterviews

Buy Evertz Technologies for the dividend, Bruce Murray says

>Two minute read on Evertz Technologies stock

Looking at it track record, Evertz Technologies (Evertz Technologies stock Quote, Chart TSX:ET) definitely falls outside of the growth stock category, but that’s okay, says portfolio manager Bruce Murray, who owns the company for its healthy dividend.

Manufacturer of video and audio technology for the broadcast TV market, Burlington, Ontario’s Evertz has had what you’d call a consistent performance over the dozen years since its IPO in 2006. Aside from a late-2007 peak where it shot up to $42 per share, ET has stayed pretty much within the $15 to $20 price range, only modestly better than its IPO at $10.25 a share.

But consistency is not a problem when the dividend keeps coming, says Murray, CEO and chief investment officer at the Murray Wealth Group.

Why own Evertz Technologies stock?

“Evertz is a company that we own in our dividend fund,” says Murray to BNN Bloomberg. “It’s a very well-run company but the market for TV studios and stuff is rather limited. They’re quite profitable and they accumulate cash and every couple of years they pay an extra dividend.”

“They’ve got a nice little dividend yield of 3.5 or 4.0 per cent and then every two to three years you get another five to ten per cent dividend,” says Murray.

Last week, Evertz’s share price jumped on its fiscal first quarter 2019 financial report which included quarterly revenue of $103.1 million, net earnings of $17.4 million (a 32 per cent year-over-year increase) and fully diluted EPS of $0.23 per share (a 35 per cent year-over-year increase). Both revenue and EPS arrived in line with analysts’ expectations. The company declared on September 11 a regular quarterly dividend of $0.18 per share.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago